CTS-3497

Phase I: Primary objective: To evaluate the safety and tolerability of CTS3497 in patients with solid tumors and lymphomas, and to determine the maximum tolerated dose and/or Phase II recommended dose. Secondary objectives: 1. To evaluate the pharmacokinetic (PK) characteristics, preliminary anti-tumor activity, and effects on the quality of life of patients with solid tumors and lymphomas of CTS3497 in patients with solid tumors and lymphomas. Exploratory objectives: 1. To explore the relationship between the degree of MTAP deficiency and the efficacy of CTS3497 in patients with MTAP-deficient solid tumors and lymphomas, the effects on the neurological function of patients with gliomas, and the pharmacodynamic (PD) characteristics in patients with solid tumors and lymphomas. 4. To explore the metabolites of CTS3497 in patients with solid tumors and lymphomas. Phase II: Primary objective: To evaluate the preliminary anti-tumor activity of selected doses of CTS3497 in patients with MTAP-deficient solid tumors and lymphomas. Secondary objectives: To evaluate the safety, antitumor activity, PK characteristics, PD characteristics, and the effects on the quality of life of patients with MTAP-deficient solid tumors and lymphomas at selected doses of CTS3497. Exploratory objectives: To explore the relationship between the degree of MTAP deficiency and the efficacy of CTS3497 in patients with MTAP-deficient solid tumors and lymphomas, and the effects of CTS3497 capsules on the neurological function of patients with gliomas.